Expression of Sodium-glucose Co-transporter 2 in Human Heart (SGLT2-MICRA)
Expression of Sodium Glucose Co-transporter2 in Myocardium From Patients With Aortic Valve Stenosis and With/Without Diastolic Heart Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jean Philippe MAZZUCOTELLI, Professor
- Phone Number: 0033 369555703
- Email: Jean-Philippe.MAZZUCOTELLI@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67098
- Hopitaux Universitaires de Strasbourg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- adults over 18 years-old
- Patient with surgical aortic valve stenosis, with or without heart failure, in two equal-sized groups (40 subjects in each group)
- Subjects affiliated with a social security health insurance plan
- Subject able to understand the objectives and risks of the research and to give dated and signed informed consent
Exclusion Criteria:
- Infective endocarditis in aortic stenosis
- Severe coronary pathology associated with aortic stenosis
- Impossible to give the subject informed information (subject in emergency situation, difficulties in understanding the subject, ...)
- Subject under legal protection
- Subject under guardianship or curatorship
- Pregnancy and/or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: patients with aortic valve stenosis with heart failure
|
The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
|
|
Experimental: patients with aortic valve stenosis without heart failure
|
The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To study the expression levels of SGLT2 in the myocardium of patients with surgical aortic stenosis
Time Frame: Day 0
|
Measure of SGLT2 expression level by RT-PCR and
|
Day 0
|
|
To study the SGLT2 tissue localization in the myocardium of patients with surgical aortic stenosis
Time Frame: Day 0
|
SGLT2 expression level by immunofluorescence labeling
|
Day 0
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of SGLT2 expression levels between heart failure and non-heart failure patients.
Time Frame: Day 0
|
SGLT2 expression levels between the 2 groups of patients
|
Day 0
|
|
Assess oxidative stress
Time Frame: Day 0
|
Pro-oxidant response (fluorescence level of the redox-sensitive fluorescent probe DHE)
|
Day 0
|
|
Evaluate the pro-inflammatory response by analysing the expression level of tissue activation molecules VCAM-1, ICAM-1, MCP-1
Time Frame: Day 0
|
Pro-inflammatory response: (VCAM-1, ICAM-1, MCP-1).
Expression level of tissue activation molecules VCAM-1, ICAM-1, MCP-1 by RT-PCR, Western blot analysis and immunofluorescence labeling
|
Day 0
|
|
Evaluate the pro-fibrotic response
Time Frame: Day 0
|
Pro-fibrotic response: TGF beta, Ang II, AT1R, ACE, collagen; MMP-2, MMP-9.
Expression level of molecules involved in tissue remodeling TGF beta, Ang II, AT1R, ACE, collagen, MMP-2, MMP-9 by RT-PCR, Western blot analysis and immunofluorescence labeling
|
Day 0
|
|
Evaluate the pro-senescent response
Time Frame: Day 0
|
Pro-senescent response: SA-beta-galactosidase activity, p53, p21, P16.
Determination of senescence-associated beta-galactosidase activity on cardiac muscle cryosections, and expression level of senescence mediators p53, p21, p16 by RT-PCR, Western blot analysis and immunofluorescence labeling
|
Day 0
|
|
Evaluate the pro-thrombotic response
Time Frame: Day 0
|
Pro-thrombotic response: tissue factor.
Expression level of coagulation cascade activator, tissue factor by RT-PCR, Western blot analysis and immunofluorescence labeling
|
Day 0
|
|
Evaluate endothelial dysfunction
Time Frame: Day 0
|
Endothelial response: eNOS, NO, nitrotyrosine.
Expression level of eNOS and nitrotyrosine by RT-PCR, Western blot analysis and immunofluorescence labeling and NO formation using the NO-sensitive fluorescent probe, DAF-FM on heart muscle cryosections
|
Day 0
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 8774 (Duke legacy protocol number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.